Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
- 1 June 2017
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 5 (6) , 446-454
Abstract
The combination of anti-VEGF blockade (bevacizumab) with immune checkpoint anti–CTLA-4 blockade (ipilimumab) in a phase I study showed tumor endothelial activation and immune cell infiltration that were associated with favorable clinical outcomes in patients with metastatic melanoma. To identify potential immune targets responsible for these observations, posttreatment plasma from long-term responding patients were used to screen human protein arrays. We reported that ipilimumab plus bevacizumab therapy elicited humoral immune responses to galectin-1 (Gal-1), which exhibits protumor, proangiogenesis, and immunosuppressive activities in 37.2% of treated patients. Gal-1 antibodies purified from posttreatment plasma suppressed the binding of Gal-1 to CD45, a T-cell surface receptor that transduces apoptotic signals upon binding to extracellular Gal-1. Antibody responses to Gal-1 were found more frequently in the group of patients with therapeutic responses and correlated with improved overall survival. In contrast, another subgroup of treated patients had increased circulating Gal-1 protein instead, and they had reduced overall survival. Our findings suggest that humoral immunity to Gal-1 may contribute to the efficacy of anti-VEGF and anti–CTLA-4 combination therapy. Gal-1 may offer an additional therapeutic target linking anti-angiogenesis and immune checkpoint blockade. Cancer Immunol Res; 5(6); 446–54. ©2017 AACR.Keywords
All Related Versions
This publication has 46 references indexed in Scilit:
- A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced DiseaseCancer Research, 2013
- Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcomaJournal of Experimental Medicine, 2012
- Metabolic Inhibition of Galectin-1-Binding Carbohydrates Accentuates Antitumor ImmunityJournal of Investigative Dermatology, 2012
- Active Immunotherapy Induces Antibody Responses That Target Tumor AngiogenesisCancer Research, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of CancerCancer Research, 2010
- The Galectin Profile of the EndotheliumThe American Journal of Pathology, 2008
- Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapyProceedings of the National Academy of Sciences, 2006
- Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicityProceedings of the National Academy of Sciences, 2006
- Checkpoint Blockade in Cancer Immunotherapy2006